Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;7(3):270-9.
doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S Albert  1 , Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen, Peter J Snyder, Maria C Carrillo, Bill Thies, Creighton H Phelps
Affiliations

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S Albert et al. Alzheimers Dement. 2011 May.

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

PubMed Disclaimer

Conflict of interest statement

With regard to potential conflicts of interest, Marilyn Albert serves as a consultant to Genentech and Eli Lilly and receives grants to her institution from GE Healthcare. Steven DeKosky serves as a consultant to Eisai, Merck, Elan/Wyeth, Novartis, he serves on the advisory board of Pfizer and provides clinical services to United Healthcare. Dennis Dickson report no conflicts. Bruno Dubois serves as a consultant to Affiris, Pierre Fabre, and Eisai, serving on a scientific advisory board for Bristol-Meyers Squibb, Roche, Pfizer, Eli Lilly, and GE Healthcare, and receives grants to his institution from Novartis, Roche, and Eisai. Howard Feldman is an employee of Bristol Meyers Squibb (BMS) and holds stock in BMS; he serves as a consultant to Servier, Glia Scientific, and Pfizer, and serves on a scientific advisory board for Elan, Janssen, Canada, and Wyeth. Nick Fox serves as a consultant (payment to Institute of Neurology) for BMS, Elan/Janssen, Eli Lilly, GE, Lundbeck, and Pfizer/Wyeth. The Institute of Neurology (Nick Fox) has conducted image analysis for Elan/Janssen, Lundbeck, and Pfizer/Wyeth. Anthony Gamst reports no conflicts. David Holtzman serves as a consultant for Bristol-Myers Squibb, Pfizer, and Innogenetics; he serves on a scientific advisory board for En Vivo, Satori, and C2N Diagnostics; and receives grants to his institution from Pfizer, Eli Lilly, and Astra Zeneca. William Jagust serves as a consultant to Genentech, Bayer Healthcare, GE Healthcare. Synarc, Otsuka Pharmaceuticals, Janssen Alzheimer Immunotherapy, Merck, and Tau Rx. Ronald Petersen serves as a consultant for Elan Pharmaceuticals and GE Healthcare and serves on data monitoring committees for Pfizer, Inc., Janssen Alzheimer Immunotherapy. Peter Snyder serves as a consultant to CogState Ltd. Maria Carrillo is an employee of the Alzheimer’s Association and reports no conflicts. Bill Thies is an employee of the Alzheimer’s Association and reports no conflicts. Creighton Phelps is an employee of the U.S. Government and reports no conflicts.

Comment in

References

    1. Jack CR, Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62. - PMC - PubMed
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. - PMC - PubMed
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. - PMC - PubMed
    1. Lyketsos C, Colenda C, Beck C, Blank K, Doraiswamy M, Kalunian D, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14:561–72. - PubMed
    1. Petersen RC, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8. - PubMed

Publication types

MeSH terms